采用甲胺和黄素进行二次初级头癌预防试验的二次二次因子设计
Vikram Kekatpure1, Narayana Subramaniam2, Sumsum Sunny3
1Department of Head Neck Oncology, Cytecare Cancer Hospital, Bangalore, India.
Asian Pacific journal of cancer prevention : APJCP
|June 25, 2024
概括
这项研究方案使用2x2的因数设计来研究甲胺和黄素用于预防头部和部状细胞癌 (HNSCC) 的第二次原发性瘤. 该试验旨在评估这种药物组合在HNSCC幸存者的安全性和有效性.
科学领域:
- 在瘤学瘤学.
- 临床试验设计 临床试验设计
- 化学预防 化学预防
背景情况:
- 头部和部状细胞癌 (HNSCC) 的幸存者面临着第二次原发性瘤 (SPT) 的高风险.
- 临床前研究表明,甲和黄素有可能预防HNSCC的发展和进展.
- 需要一个强大的临床试验设计来评估用于SPT预防的组合治疗.
研究的目的:
- 描述一项临床试验的协议,评估在HNSCC患者中用于SPT预防的甲胺和黄素.
- 为了确定甲胺和黄素的安全性和有效性,单独或组合,作为化学预防剂.
- 探索潜在的生物标志物和二次终点,包括复发和毒性.
主要方法:
- 这是一项大型IIB/III期,双盲,多中心,安慰剂控制,随机临床试验,涉及1500名HNSCC患者.
- 应用2x2因子设计,同时评估甲胺和黄素的作用及其相互作用.
- 治疗臂包括梅特福林 (与安慰剂),库尔库 (与安慰剂),组合梅特福林和库尔库,或单独安慰剂36个月.
主要成果:
- 主要终点是空气消化道中SPT的发生率.
- 二级终点包括评估与治疗相关的毒性,SPT复发率,以及识别潜在的预测生物标志物.
- 2x2因子设计允许有效评估单个药物效应及其综合影响.
结论:
- 2x2因子设计是测试多种干预措施的化学预防试验的有效策略.
- 这种试验设计使药物疗效和相互作用的并行评估更容易,而不会显著增加样本大小.
- 该研究协议为评估HNSCCSPT预防中的甲胺和黄素提供了一个框架.
相关概念视频
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
01:21Cancer Survival Analysis
342
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
342
01:20Comparing the Survival Analysis of Two or More Groups
177
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
177
01:12Hazard Ratio
111
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
111
02:59Cancer Prevention
6.1K
Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Some...
6.1K